Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

ADC and CDK4/6 Inhibitor Decision-Making and Sequencing Questions Abound in Breast Cancer

October 8th 2024

Yuan Yuan, MD, PhD, discusses post-CDK4/6 inhibitor treatment options for HR-positive breast cancer and expansions of the definition of HER2 expression.

Next Generation of CDK Inhibitors Are Breaking Ground in HER2– Breast Cancer

October 7th 2024

Joseph A. Sparano, MD, details the next generation of CDK inhibitors such as BLU-222 targeting CDK2 and PF-07220060 targeting CDK4.

The OncFive: Top Oncology Articles for the Week of 9/29

October 5th 2024

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

Research Seeks to Establish the Efficacy of Minimally Invasive Breast Cancer Procedures and Tests

October 5th 2024

Yuan Yuan, MD, PhD, discusses the management of node-positive breast cancer and the need for guidance surrounding the use of ctDNA in breast cancer.

OncLive’s September Roundup of Key FDA Approvals in Oncology

October 4th 2024

Here is your snapshot of all treatment options that the FDA approved in September 2024.

Dr McAndrew on a Subgroup Analysis of NATALEE in HR+/HER2– Early Breast Cancer

October 3rd 2024

Nicholas P. McAndrew, MD, MSCE, discusses a subgroup analysis of the NATALEE trial in HR+/HER2– early breast cancer by prior systemic treatment.

Dr Hu on the Evaluation of Tibremciclib Plus Fulvestrant in HR+/HER2– Advanced Breast Cancer

October 3rd 2024

Xichun Hu, MD, PhD, discusses a study of tibremciclib plus fulvestrant in HR+/HER2– advanced breast cancer following progression on endocrine therapy.

Bria-IMT Plus Immunotherapy Shows Early Promise in Breast Cancer Brain Metastasis

October 2nd 2024

Bria-IMT plus an immune checkpoint inhibitor completely resolved a breast cancer metastasis and shrunk an eye-bulging orbital lesion in 1 patient.

Key Takeaways and Clinical Practice Pearls in the Treatment of Patients with Breast Cancer Receiving ADCs

October 2nd 2024

Panelists discuss how addressing unmet needs in patient selection, resistance mechanisms, and long-term outcomes can enhance the efficacy of antibody-drug conjugates in breast cancer treatment.

De-Escalated Neoadjuvant Treatment Does Not Compromise Survival Outcomes in HR+/HER2+ Early Breast Cancer

October 2nd 2024

Oleg Gluz, MD, highlights the feasibility of de-escalated neoadjuvant therapy plus trastuzumab and pertuzumab in patients with HR+/HER2+ breast cancer.

FDA Grants Priority Review to T-DXd in HR+, HER2-Low/-Ultralow Breast Cancer

October 1st 2024

The sBLA for trastuzumab deruxtecan in hormone receptor–positive, HER2-low or -ultralow breast cancer has been accepted for priority review by the FDA.

Dr Ma on Mechanisms of Resistance to CDK4/6 Inhibitors in HR+ Breast Cancer

September 27th 2024

Cynthia X. Ma, MD, PhD, discusses current unmet needs associated with the use of CDK4/6 inhibitors in the treatment of breast cancer.

Breast Cancer Experts Spotlight Early-Phase and Real-World Research at the 2024 ESMO Congress

September 26th 2024

Breast cancer experts highlight early-phase and real-world studies of interest from the 2024 ESMO Congress.

Risk of Lymphedema Is Comparable With Hypofractionated Radiation in Early Breast Cancer

September 26th 2024

The risk of lymphedema was comparable for hypofractionated radiation therapy and normofractionated radiation therapy in early breast cancer.

Adjuvant Ribociclib Approval Expands Access to CDK4/6 Inhibition in High-Risk HR+/HER2– Breast Cancer

September 25th 2024

Bora Lim, MD, discusses the significance of the FDA approval of adjuvant ribociclib for patients with HR-positive, HER2-negative breast cancer.

Dr Partridge on Unique Treatment Challenges for Young Patients with ER+/Node-Positive Breast Cancer

September 25th 2024

Ann H. Partridge, MD, MPH, discusses unique challenges associated with very young patients who have ER+/node-positive breast cancer.

Expert Insights: Investigational ADCs Safety Profiles

September 25th 2024

Panelists discuss how, despite the investigational status of agents like patritumab deruxtecan (HER3-DXd) and datopotamab deruxtecan (Dato-DXd), it’s crucial for community oncologists to be aware of the treatment-related adverse effects (TRAEs) associated with these therapies and to consider effective management strategies as reported in clinical trials.

No Significant PFS Association Is Seen Between Chemotherapy Backbone and HRD Status in First-Line TNBC

September 25th 2024

A statistically significant difference in PFS was not observed between chemotherapy backbone and HRD status in first-line TNBC.

Dr Kaklamani on the Role of Adjuvant Ribociclib in Early-Stage HR+/HER2– Breast Cancer

September 24th 2024

Virginia Kaklamani, MD, discusses the optimal role for adjuvant ribociclib alongside endocrine therapy in early-stage HR+/HER2– breast cancer.

Future Perspectives on ADCs in Breast Cancer

September 24th 2024

Panelists discuss how ongoing clinical trials of investigational antibody-drug conjugates (ADCs) are advancing treatment options for breast cancer, particularly in patients with active brain metastases and advanced disease.